NASDAQ: SYBX - Synlogic, Inc.

Rentabilidad a seis meses: -4.9%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción Synlogic, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa Synlogic, Inc.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States.

más detalles
Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

IPO date 2015-10-01
ISIN US87166L1008
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.synlogictx.com
Цена ао 1.78
Cambio de precio por día: -3.55% (1.4101)
Cambio de precio por semana.: -4.23% (1.42)
Cambio de precio por mes: -3.55% (1.41)
Cambio de precio en 3 meses.: -11.11% (1.53)
Cambio de precio en seis meses: -4.9% (1.43)
Cambio de precio por año: -64.68% (3.85)
Cambio de precio en 3 años.: -43.57% (2.41)
Cambio de precio en 5 años.: -35.85% (2.12)
Cambio de precio en 10 años.: -0% (1.36)
Cambio de precio desde principios de año.: -6.85% (1.46)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 7.02 1
P/BV 0.5549 10
P/E 0 0
EV/EBITDA -0.3314 0
Total: 5.13

Eficiencia

Nombre Significado Calificación
ROA, % -75.82 0
ROE, % -134.29 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.3371 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 53.23 7
Rentabilidad Ebitda, % 1.4 1
Rentabilidad EPS, % 447.18 10
Total: 4.2
Más detalles

Instituciones Volumen Compartir, %
NEA Management Company, LLC 2922774 25.09
Armistice Capital, LLC 1055000 9.06
FMR, LLC 258644 2.22
Vanguard Group Inc 188433 1.62
Alyeska Investment Group, L.P. 55872 0.48
Renaissance Technologies, LLC 54630 0.47
Geode Capital Management, LLC 44423 0.38
Harbor Capital Advisors, Inc. 30685 0.26
Fiduciary Trust Company (MA) 22352 0.19
Ikarian Capital, LLC 20448 0.18



Supervisor Título profesional Pago año de nacimiento
Mr. Antoine Awad Principal Executive Officer 580.33k 1980 (45 años)
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1981 (44 año)
Dr. James J. Collins Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1966 (59 años)
Ms. Mary Beth Dooley VP, Head of Finance and Principal Financial Officer & Principal Accounting Officer N/A 1981 (44 año)
Mr. Ajay Munshi Vice President of Corporate Development N/A
Ms. Molly Harper Chief Business Officer N/A 1977 (48 años)
Dr. Neal Sondheimer M.D., Ph.D. VP & Head of Clinical N/A
Dr. Mylene Perreault Ph.D. VP & Head of Research
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Advisor 1962 (63 año)

DIRECCIÓN: United States, Cambridge. MA, 301 Binney Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.synlogictx.com